Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc. held its 2026 Annual Shareholders' Meeting, where shareholders approved all proposals. Key approvals included the election of all nominated directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and the non-binding advisory approval of executive officer compensation. Most significantly, shareholders approved the Second Amended and Restated 2008 Incentive Compensation Plan, which increases the number of shares available for issuance under the plan by 8,000,000.

Pediatrix Medical Group reported a significant increase in net income and diluted earnings per share for the first quarter of 2026. Net income rose by 42.6% to $29.57 million, with diluted EPS increasing by 50% to $0.36. The company also completed the acquisition of a maternal-fetal medicine practice for $7.9 million and repurchased 1.0 million shares of its common stock for $19.9 million during the quarter.

Pediatrix Medical Group reported strong first-quarter results for 2026, with Adjusted EPS of $0.44 and net revenue of $476.2 million, exceeding expectations due to top-line growth. Net income increased to $29.6 million from $20.7 million in the prior-year period. The company reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million, highlighting a healthy balance sheet and robust cash flow for future opportunities.